Press Releases

HOUSTON, Aug. 14, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the Company has treated the first patients

INDIANAPOLIS, Aug. 14, 2019 /PRNewswire/ -- Athletico Physical Therapy has opened its 6th location in Indianapolis on Wednesday, August 14th and the 30th location in central Indiana. It is conveniently located in the Willow Lake West strip mall near

DALLAS, Aug. 14, 2019 /PRNewswire/ -- New research from Parks Associates finds 15% of US broadband households have

PARKLAND, Fla., Aug. 14, 2019 /PRNewswire/ -- Parkland Cares has awarded $239,000 to six mental health-counseling centers and now the nonprofit, which focus

VANCOUVER and HOUSTON, Aug. 14, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended

• Second Quarter Adjusted Total Revenue - $19.1 million •• Second Quarter Adjusted EBITDA - $5.7 million •• Second Quarter Gross Profit - $9.6 million •

GERMANTOWN, Md., Aug. 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, reported its financial results for the second quarter ended June 30, 2019.RECENT HIGHLIGHTS & ACCO

MONMOUTH JUNCTION, N.J., Aug. 14, 2019 /PRNewswire/ -- Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved New Drug Applications and a late-stage pipeline of innovative product candidates for the treatment of Attention-Deficit Hyperactivity Disorder and related disorders, is announcing that its Chief Medical Officer,

KELOWNA, BC, Aug. 14, 2019 /PRNewswire/ - Valens GroWorks Corp. (TSXV: VGW) (OTC: VGWCF) (the "Company" or "Valens"), a vertically integrated provider of industry leading extraction products and services; including a diverse suite of extraction methodologies, next generation cannabinoid delivery formats and an ISO 17025 accredited analytical la

FDA Accepts New Drug Application for BrinavessTM; PDUFA Date Set for December 24, 2019Recently Strengthened Balance Sheet Extends Cash Runway Into Mid-2020Management to Host Conference Call and Webcast Today, August 14, 2019 at